Antimicrobial Susceptibility Breakpoints and First-Step parC Mutations in Streptococcus pneumoniae: Redefining Fluoroquinolone Resistance
2003

Understanding Fluoroquinolone Resistance in Streptococcus pneumoniae

Sample size: 115 publication Evidence: moderate

Author Information

Author(s): Lim Sue, Bast Darrin, McGeer Allison, de Azavedo Joyce, Low Donald E.

Primary Institution: Toronto Medical Laboratories/Mount Sinai Hospital

Hypothesis

Can levofloxacin breakpoints effectively identify Streptococcus pneumoniae isolates with resistance mechanisms?

Conclusion

Levofloxacin susceptibility testing using current clinical breakpoints fails to identify most S. pneumoniae isolates with first-step parC mutations.

Supporting Evidence

  • 59% of isolates with a levofloxacin MIC of 2 μg/mL had a first-step mutation in parC.
  • Current NCCLS breakpoints do not effectively detect emerging fluoroquinolone resistance.
  • First-step mutations in parC are associated with decreased susceptibility to fluoroquinolones.

Takeaway

This study found that many bacteria thought to be treatable with levofloxacin actually have mutations that make them resistant, even if tests say they're okay.

Methodology

The study examined 115 S. pneumoniae isolates for parC mutations and performed susceptibility testing using NCCLS guidelines.

Limitations

The study may not account for all resistance mechanisms and relies on specific breakpoints that may not be accurate.

Digital Object Identifier (DOI)

10.3201/eid0907.020589

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication